Ozmosi | Artemether Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Artemether

Alternative Names: artemether, artemeter
Clinical Status: Inactive
Latest Update: 2025-11-19
Latest Update Note: Clinical Trial Update

Product Description

an alternative artemisinin derivative. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25209020/)

Mechanisms of Action: ATPase Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | China | Colombia | Ecuador | Egypt | France | Germany | Greece | India | Indonesia | Ireland | Japan | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Portugal | Slovenia | South Africa | Spain | Sweden | Switzerland | Thailand | Ukraine | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Ministry of Health
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Artemether

Countries in Clinic: Bangladesh, Burkina Faso, Cambodia, Guinea, Niger, Nigeria, Rwanda, Tanzania, Thailand, Unknown Location

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Malaria, Falciparum

Phase 1: HIV Infections|Hepatitis B|Pregnancy Outcomes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT04080895

 ALAQ

P1

Recruiting

HIV Infections|Hepatitis B|Pregnancy Outcomes

2026-08-31

2024-03-07

NCT03923725

 DeTACT-Africa

P3

Completed

Malaria, Falciparum

2024-03-15

2025-11-19

Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT03939104

 DeTACT-ASIA

P3

Completed

Malaria, Falciparum

2023-01-06

2024-03-21

Recent News Events

Date

Type

Title

11/12/2025

News Article

 Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

07/17/2025

News Article

 Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance

07/08/2025

News Article

 Novartis receives approval for first malaria medicine for newborn babies and young infants

05/02/2025

News Article

 Imperative Appoints John Nagulendran as Chief Growth & Investment Officer and Member of the Board

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions